It's Wednesday evening, but before you shut it down for the night, I need a few minutes of attention.

SmallCapFirm

Could Past Champ (AVCO) Look To Go Running Again With Help From 4 Key Potential Catalysts? (Low Float)

August 3rd

SCF Readers,

It's Wednesday evening, but before you shut it down for the night, I need a few minutes of attention.

I've been tracking a specific Nasdaq breakout idea closely and believe now is the time to get it back on your radar.

Back on your radar? That's right. This is a past champ.

Coming to your attention earlier in 2022, this profile made an approximate 20% short term run from the end of January into the beginning of February after my alert.

And after we caught news that an insider was buying last week, this company could start popping up on radars everywhere.

Plus, consider some of my recent profiles that were also under the radar breakout ideas.

We've seen them turn into approximate intraday/short term runners of: 24%, 53%, 33%, and 18%.

Could this be the next Nasdaq profile to fall in line?

Based on huge company news announcements in 2022, and a chart that shows a profile that might be itching to breakout as it recently moved above several lines of potential support, there is only one low float idea to have on screen now:

*Avalon GloboCare Corp. (AVCO)*

Avalon GloboCare Corp. (NASDAQ: AVCO) is a clinical-stage, vertically integrated, leading CellTech bio-developer dedicated to advancing and empowering innovative, transformative immune effector cell therapy, exosome-based ACTEX technology, as well as cell therapy related companion diagnostics.

And right now, AVCO has 4 potential breakout catalysts that are must-know material. Check them out:

No. 1 - A Game-Changing New Study Featuring AI Enhanced Protein Design "QTY Code" Tech

No. 2 - Count Them: 16 New Patent Applications Filed

No. 3 - Low Float Profile Provides Possibility For Daily Volatility

No. 4 - Company Signs MOU With "Prestigious" Hematology Institute (Could Expand AVCO's Pipeline Immensely)

But more on those in a second...

It All Starts With Your Body’s T-Cells…

They’re your immune system’s frontline soldiers in the fight against common infections and everyday maladies.

When you’re stuck at home on bedrest, your T-Cells are hard at work getting you back into healthy shape.

Though, they may not always be ready to take on the tougher conditions.

That’s where Chimeric Antigen Receptor T-Cell (or “CAR-T”) therapy comes in.

Experts refer to CAR-T therapy as a potential “Living Cure” for some of the world’s deadliest diseases.

Even in its earliest forms as a treatment for blood cancer, this relatively non-invasive treatment leads to lasting remission in no less than 30-40% of patients.

But one company could potentially drive that success rate much higher…

Avalon GloboCare’s Revolutionary Research

image

Avalon is a clinical-stage, vertically integrated, leading “CellTech” bio-developer dedicated to advancing and empowering innovative, transformative immune effector cell therapy, exosome technology, as well related diagnostics and therapeutics.

The Company also provides strategic advisory and outsourcing services to facilitate and enhance its clients’ growth and development, as well as competitiveness in healthcare and CellTech industry markets.

Through its subsidiary structure with unique integration of verticals from innovative R&D to automated bioproduction and accelerated clinical development, the Company is establishing a leading role in the fields of cellular immunotherapy (including CAR-T/NK), exosome technology (ACTEX™), and other related vaccine and therapeutics.

Their core focus at the moment is their 3rd Generation CAR-T therapy that can potentially be useful in the treatment of cancer and other life-threatening diseases along with their FLASH-CAR technology and stem cell derived Exosome technology called ACTEX. ACTEX can be used to treat a wide variety of conditions, from neurodegenerative disorders to immune health, orthopedic applications, wound management and even weight management.

Avalon GloboCare successfully filed for a $50Mn shelf offering (S3) in January of 2019, and was also staked a $20Mn credit facility from Chairman Daniel Lu.

That same Daniel Lu also happens to be chairman of the Lu DaoPei hospital group, China’s largest hematology and CAR-T treatment center.

Those types of connections are key to Avalon GloboCare’s vertical integration:

Upstream: Innovation, R&D, IPs

- QTY-code engineered novel targets; AVA-Trap ™

- Next-Gen multi-target, RNA-based Flash-CAR ™

- Angiogenic Exosomes; ACTEX ™

Midstream: Process development, Bio-production, QC/QA

- UPMC: Accredited cGMP/cGTP/FACT/aaBB/CLIA/CAP Facility

Downstream: Clinical Programs

- Medical Team: Lu Daopei Hospital network and over 100 affiliated hospitals, the world’s single largest BMT and CAR-T treatment center;

- Commercialization: B-to-B model for product development and global marketing (ACTEX ™ecosystem)

This kind of integration is a tremendous advantage for companies working in the clinical stage of the process, because it gives Avalon GloboCare a real-world path to market (and to potential revenues) without the imminent need to involve third parties or secure new funding.

That means the company has a direct pipeline that can take compelling research and new ideas, rapidly transform them into a marketable product, and then potentially fast-track the testing process.

Their lead CAR-T candidate, AVA-001, has already completed a pilot first-in-human trial in patients with B-cell acute lymphoblastic leukemia with a stated remission rate far higher than the industry standard.

Avalon is currently expanding patient recruitment and indication.

Read more key details at the company website and check out their presentation here.

-----

And right now, 4 potential catalysts could fuel a vertical chart move in the near term for AVCO. They are:

No. 1 AVCO Potential Catalyst - A Game-Changing New Study Featuring AI Enhanced Protein Design "QTY Code" Tech

Avalon GloboCare Announces New Study Featuring AI-Enhanced Protein Design Technology Targeting Glucose Transporter Against Cancer

FREEHOLD, N.J., June 30, 2022 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a leading global developer of innovative cell-based technologies and therapeutics, today announced a new study applying artificial intelligence (AI) enhanced protein design “QTY Code” technology. The method is expected to accelerate development of therapeutic monoclonal antibodies to treat cancer.

...

Read the full article here.

-----

No. 2 AVCO Potential Catalyst - Count Them: 16 New Patent Applications Filed

Avalon GloboCare Expands IP Portfolio; Files 16 New Patent Applications

Co-inventors are leading international universities and cellular therapy developers

Patent applications cover three types of cellular therapies and related technologies

Read the full article here.

-----

No. 3 AVCO Potential Catalyst - Low Float Profile Provides Possibility For Daily Volatility

At 31.39Mn shares, the Yahoo Finance website is reporting AVCO to have relatively small float.

In recent days, we've noticed a few, big, intraday green spikes on AVCO's chart.

Could volatility from so few shares available be leading to this?

-----

No. 4 AVCO Potential Catalyst - Company Signs MOU With "Prestigious" Hematology Institute (Could Expand AVCO's Pipeline Immensely)

Avalon GloboCare Signs MOU...

From the article:

It is an honor to form this strategic collaboration with the researchers and clinicians at the prestigious Lu Daopei Hematology Institute to advance the clinical development of potentially breakthrough cellular immunotherapies along with companion diagnostics,” said David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon GloboCare.

Read the full article here.

-----

AVCO Recap: 4 Potential Catalysts Could Fuel A Vertical Move For This Nasdaq Profile

No. 1 - A Game-Changing New Study Featuring AI Enhanced Protein Design "QTY Code" Tech

No. 2 - Count Them: 16 New Patent Applications Filed

No. 3 - Low Float Profile Provides Possibility For Daily Volatility

No. 4 - Company Signs MOU With "Prestigious" Hematology Institute (Could Expand AVCO's Pipeline Immensely)

-----

Coverage is officially initiated on AVCO. When time permits, do this:

image

Get AVCO on your radar now.

Sincerely,

Axel Adams

Editor, SCF


(Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)​

StockWireNews (stockwirenews . com) is owned by SWN Media LLC, a limited liability company (SWN Media LLC has recently retained ownership of StockNewsWire LLC). Disclosure: Make sure to always do your own research and due diligence on any day and swing trade profile I bring to your attention. I am not a license d finan.cial advise r. All potential percentage gains are based on from the low to the high of day. SmallCapFirm's full disclosure is to be read and fully understood before using SmallCapFirm's website, or joining SmallCapFirm's email or text list. By viewing SmallCapFirm's website and/or reading SmallCapFirm's email or text newsletter you are agreeing to SmallCapFirm's full disclosure which can be read at: smallcapfirm.com/disclosure StockWireNews (stockwirenews . com) is owned by SWN Media LLC, a limited liability company (SWN Media LLC has recently retained ownership of StockNewsWire LLC). An owner of SWN Media LLC owns and operates smallcapfirm . com (“SCF”), owns an interest in the limited liability company that owns and operates fierceinvestor . com (“FI”), an interest in the limited liability company that owns and operates stockstreetwire . com (SSW), and an interest in the limited liability company that owns and operates nasdaqwirenews . com (NWN) . From time to time, StockWireNews, SCF, FI, SSW, and/or NWN will publicly disseminate information about a company via website, email, SMS and other points of media. Pursuant to an agreement between SWN Media LLC and Legends Media LLC, SmallCapFirm (SCF) has been hired for a period beginning on 1/31/22 and ending on 2/1/22 to publicly disseminate information about (AVCO) via Website, Email and SMS. SWN Media LLC was paid twenty-seven thousand five hundred USD via bank wire transfer. We own zero shares of (AVCO). Pursuant to an agreement between SWN Media LLC and TD Media LLC, SmallCapFirm (SCF) has been hired for a period beginning on 8/3/22 and ending on 8/4/22 to publicly disseminate information about (AVCO) via Website, Email and SMS. SWN Media LLC was paid seven thousand five hundred USD via bank wire transfer. We own zero shares of (AVCO). To date we have been compensated a total of thirty-five thousand USD via bank wire transfer to disseminate information about (AVCO).